TEVA-FLUCONAZOLE TABLET

Pajjiż: Kanada

Lingwa: Ingliż

Sors: Health Canada

Ingredjent attiv:

FLUCONAZOLE

Disponibbli minn:

TEVA CANADA LIMITED

Kodiċi ATC:

J02AC01

INN (Isem Internazzjonali):

FLUCONAZOLE

Dożaġġ:

50MG

Għamla farmaċewtika:

TABLET

Kompożizzjoni:

FLUCONAZOLE 50MG

Rotta amministrattiva:

ORAL

Unitajiet fil-pakkett:

50/100/500/1000

Tip ta 'preskrizzjoni:

Prescription

Żona terapewtika:

AZOLES

Sommarju tal-prodott:

Active ingredient group (AIG) number: 0122529001; AHFS:

L-istatus ta 'awtorizzazzjoni:

APPROVED

Data ta 'l-awtorizzazzjoni:

2002-06-06

Karatteristiċi tal-prodott

TEVA-FLUCONAZOLE
(
Fluconazole Tablets
)
Page 1 of 53
_ _
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
PR
TEVA-FLUCONAZOLE
Fluconazole Tablets
Tablets, 50 mg and 100 mg, Oral
Teva Standard
Antifungal Agent
Teva Canada Limited
30 Novopharm Court,
Toronto, Ontario
Canada M1B 2K9
www.tevacanada.com
Submission Control Number: 274570
Date of Initial Authorization:
August 24, 2016
Date of Revision:
June 20, 2023
TEVA-FLUCONAZOLE
(
Fluconazole Tablets
)
Page 2 of 53
_ _
RECENT MAJOR LABEL CHANGES
7 WARNINGS AND PRECAUTIONS
11/2022
9
DRUG INTERACTIONS
06/2023
TABLE OF CONTENTS
SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF
AUTHORIZATION ARE NOT LISTED.
RECENT MAJOR LABEL CHANGES
............................................................................................
2
TABLE OF CONTENTS
..............................................................................................................
2
PART I:
HEALTH PROFESSIONAL INFORMATION
................................................................. 4
1
INDICATIONS
...................................................................................................................
4
1.1
Pediatrics(<18 years of age)
............................................................................................
4
1.2
Geriatrics
..........................................................................................................................
4
2
CONTRAINDICATIONS
.....................................................................................................
5
4
DOSAGE AND ADMINISTRATION
.....................................................................................
5
4.1
Dosing Considerations
.....................................................................................................
5
4.2
Recommended Dose and Dosage Adjustment
................................................................ 5
4.4
Missed Dose
............................................................................................................